Cormedix Inc.

Cormedix Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. For more information, visit: www.cormedix.com.

Company Details

Employees
88
Founded
-
Address
300 Connell Dr,
Phone
908-517-9500
Email
jd****@****end.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Berkeley Heights, New Jersey
Looking for a particular Cormedix Inc. employee's phone or email?

Cormedix Inc. Questions

News

CorMedix Inc. Announces DefenCath Receives Innovative Technology Designation from Vizient - Quiver Quantitative

CorMedix Inc. Announces DefenCath Receives Innovative Technology Designation from Vizient Quiver Quantitative

DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation - Stock Titan

DefenCath by CorMedix (NASDAQ: CRMD) receives Vizient Innovative Technology designation Stock Titan

CorMedix Announces Strategic Minority Investment in Talphera - Yahoo Finance

CorMedix Announces Strategic Minority Investment in Talphera Yahoo Finance

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - The Manila Times

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath The Manila Times

CorMedix Completes Acquisition of Melinta Therapeutics - citybiz

CorMedix Completes Acquisition of Melinta Therapeutics citybiz

CorMedix Inc. Plans $85 Million Public Offering of Common Stock - Nasdaq

CorMedix Inc. Plans $85 Million Public Offering of Common Stock Nasdaq

At least $375M FY2025 guidance — CorMedix raises pro forma net revenue; Q3 pro forma >$125M - Stock Titan

At least $375M FY2025 guidance — CorMedix raises pro forma net revenue; Q3 pro forma >$125M Stock Titan

CorMedix Inc. Reports Q3 2025 Pro Forma Net Revenue Exceeding $125 Million and Raises Full-Year Guidance to $375 Million - Quiver Quantitative

CorMedix Inc. Reports Q3 2025 Pro Forma Net Revenue Exceeding $125 Million and Raises Full-Year Guidance to $375 Million Quiver Quantitative

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance - The Manila Times

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance The Manila Times

CorMedix Inc. Reports Q1 2025 Financial Results: $39.1 Million in Net Revenue and Positive Adjusted EBITDA of $23.6 Million - Nasdaq

CorMedix Inc. Reports Q1 2025 Financial Results: $39.1 Million in Net Revenue and Positive Adjusted EBITDA of $23.6 Million Nasdaq

Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care - Stock Titan

Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care Stock Titan

CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 | CRMD Stock News - Quiver Quantitative

CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 | CRMD Stock News Quiver Quantitative

CorMedix Inc. to Present at Upcoming Investor Conferences in September 2025 - Quiver Quantitative

CorMedix Inc. to Present at Upcoming Investor Conferences in September 2025 Quiver Quantitative

Leading Biopharma CorMedix Takes Stage at Cantor Global and Morgan Stanley Healthcare Conferences - Stock Titan

Leading Biopharma CorMedix Takes Stage at Cantor Global and Morgan Stanley Healthcare Conferences Stock Titan

$300M Pharma Deal: CorMedix Acquires Melinta's 7-Drug Portfolio, Targets $350M Revenue by 2025 - Stock Titan

$300M Pharma Deal: CorMedix Acquires Melinta's 7-Drug Portfolio, Targets $350M Revenue by 2025 Stock Titan

CorMedix Inc. Expands DefenCath Implementation with Large Dialysis Organization, Increases Q2 Net Sales Guidance - Quiver Quantitative

CorMedix Inc. Expands DefenCath Implementation with Large Dialysis Organization, Increases Q2 Net Sales Guidance Quiver Quantitative

CorMedix Announces Massive $85M Stock Offering: Strategic Acquisitions and R&D Expansion Planned - Stock Titan

CorMedix Announces Massive $85M Stock Offering: Strategic Acquisitions and R&D Expansion Planned Stock Titan

$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products - Stock Titan

$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products Stock Titan

CorMedix Expands Major Dialysis Contract, Boosts Revenue Forecast by $9M as Customer Base Grows 50% - Stock Titan

CorMedix Expands Major Dialysis Contract, Boosts Revenue Forecast by $9M as Customer Base Grows 50% Stock Titan

Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week - Stock Titan

Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week Stock Titan

CorMedix Raises $85M in Stock Offering to Fuel R&D and Strategic Acquisitions - Stock Titan

CorMedix Raises $85M in Stock Offering to Fuel R&D and Strategic Acquisitions Stock Titan

CorMedix Hits Major Milestone: First-Ever Profitable Quarter Signals Strong Growth Ahead - Stock Titan

CorMedix Hits Major Milestone: First-Ever Profitable Quarter Signals Strong Growth Ahead Stock Titan

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration Stock Titan

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team - The Manila Times

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team The Manila Times

Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? - Yahoo Finance

Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? Yahoo Finance

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? - Yahoo Finance

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? Yahoo Finance

Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability - Yahoo Finance

Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability Yahoo Finance

CorMedix Inc. (CRMD): A Bull Case Theory - Yahoo Finance

CorMedix Inc. (CRMD): A Bull Case Theory Yahoo Finance

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates Yahoo Finance

Cormedix CEO Todisco sells $650,000 in shares - Investing.com

Cormedix CEO Todisco sells $650,000 in shares Investing.com

Cormedix CEO Todisco sells $650,000 in shares - Investing.com

Cormedix CEO Todisco sells $650,000 in shares Investing.com

CorMedix to Buy Melinta Therapeutics for $300 Million - The Wall Street Journal

CorMedix to Buy Melinta Therapeutics for $300 Million The Wall Street Journal

CorMedix: The Undervalued Breakthrough (NASDAQ:CRMD) - Seeking Alpha

CorMedix: The Undervalued Breakthrough (NASDAQ:CRMD) Seeking Alpha

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership Business Wire

CorMedix: Strong Adoption Curve And Policy Environment (NASDAQ:CRMD) - Seeking Alpha

CorMedix: Strong Adoption Curve And Policy Environment (NASDAQ:CRMD) Seeking Alpha

CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell - Seeking Alpha

CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell Seeking Alpha

CorMedix Seems Significantly Undervalued (NASDAQ:CRMD) - Seeking Alpha

CorMedix Seems Significantly Undervalued (NASDAQ:CRMD) Seeking Alpha

CorMedix buys Melinta Therapeutics for $300M - ROI-NJ

CorMedix buys Melinta Therapeutics for $300M ROI-NJ

CorMedix Inc. to Present at the Cantor Global Healthcare Conference - Stock Titan

CorMedix Inc. to Present at the Cantor Global Healthcare Conference Stock Titan

CorMedix:Exceeding Expectations (NASDAQ:CRMD) - Seeking Alpha

CorMedix:Exceeding Expectations (NASDAQ:CRMD) Seeking Alpha

CorMedix completes $150 million convertible notes offering on Nasdaq - Investing.com

CorMedix completes $150 million convertible notes offering on Nasdaq Investing.com

CorMedix expands infectious disease portfolio with $300M acquisition of Melinta - Fierce Pharma

CorMedix expands infectious disease portfolio with $300M acquisition of Melinta Fierce Pharma

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug - Investor's Business Daily

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug Investor's Business Daily

CorMedix Completes Acquisition of Melinta Therapeutics - TipRanks

CorMedix Completes Acquisition of Melinta Therapeutics TipRanks

CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position - Seeking Alpha

CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position Seeking Alpha

The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha

The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) Seeking Alpha

CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha

CorMedix: A Fair-Priced Biotech Company With A Bright Future Seeking Alpha

CorMedix to buy Deerfield-backed Melinta Therapeutics - pehub.com

CorMedix to buy Deerfield-backed Melinta Therapeutics pehub.com

CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) - Seeking Alpha

CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) Seeking Alpha

CorMedix (CRMD) Q4 2024 Earnings Call Transcript - The Motley Fool

CorMedix (CRMD) Q4 2024 Earnings Call Transcript The Motley Fool

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - simplywall.st

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns simplywall.st

Cormedix Appoints Robert A. Stewart to Its Board of Directors - citybiz

Cormedix Appoints Robert A. Stewart to Its Board of Directors citybiz

CorMedix Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - citybiz

CorMedix Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update citybiz

CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool

CorMedix (CRMD) Q3 2024 Earnings Call Transcript The Motley Fool

Fresenius Medical Stock: I Believe The Company Will 'Pop' In 2024-2026 (OTCMKTS:FMCQF) - Seeking Alpha

Fresenius Medical Stock: I Believe The Company Will 'Pop' In 2024-2026 (OTCMKTS:FMCQF) Seeking Alpha

FDA slaps CorMedix with a 2nd manufacturing-related drug rejection - Fierce Pharma

FDA slaps CorMedix with a 2nd manufacturing-related drug rejection Fierce Pharma

CorMedix CEO Khoso Baluch Retires - citybiz

CorMedix CEO Khoso Baluch Retires citybiz

Top Cormedix Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant